FDA's April 30, 2026 Proposal On April 30, 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these drugs from bulk drug substances when FDA-approved versions are available
So where harm can happen is not having that whole system, that ecosystem, you know, approach for an individual on the flip side, where it can be so incredibly helpful
Some of the common ones are: Nausea Headache Stomach pain Heartburn Dizziness Mood changes Experts say its important for people prescribed GLP-1 medications to recognize that the drugs are part of a long-term treatment plan that involves lifestyle factors such as a balanced, healthy diet and regular aerobic and strength exercise
Classification Drug class: Immunosuppressant (calcineurin inhibitor) 3